With new app for FDA approval, Gilead aims for a hep C trifecta

Gilead Sciences ($GILD), already reaping billions from its duo of approved hepatitis C therapies, has submitted a third pill to the FDA. The combination therapy, which has the agency's breakthrough designation, promises to cure a wider range of patients with the virus. Report

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.